Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you) LoginRegister
Psoriasis Club is a friendly on-line Forum where people with psoriasis or psoriatic arthritis
can get together and share information, get the latest news, or just chill out with others who understand. It is totally
self funded and we don't rely on drug manufacturers or donations. We are proactive against Spammers,
Trolls, And Cyberbulying and offer a safe friendly atmosphere for our members.
So Who Joins Psoriasis Club?
We have members who have had psoriasis for years and some that are newly diagnosed. Family and friends of those with psoriasis
are also made welcome. You will find some using prescribed treatments and some using the natural approach. There are people who
join but keep a low profile, there are people who just like to help others, and there are some who just like
to escape in the Off Topic Section.
Joining Couldn't Be Easier: If you are a genuine person who would like to meet others who understand,
just hit the Register button and follow the instructions.
Members get more boards and privileges that are not available to guests.
OK So What Is Psoriasis?
Psoriasis is a chronic, autoimmune disease that appears on the skin. It
occurs when the immune system sends out faulty signals that speed up the
growth cycle of skin cells. Psoriasis is not contagious. It commonly
causes red, scaly patches to appear on the skin, although some patients
have no dermatological symptoms. The scaly patches commonly caused by
psoriasis, called psoriatic plaques, are areas of inflammation and
excessive skin production. Skin rapidly accumulates at these sites which
gives it a silvery-white appearance. Plaques frequently occur on the
skin of the elbows and knees, but can affect any area including the
scalp, palms of hands and soles of feet, and genitals. In contrast to
eczema, psoriasis is more likely to be found on the outer side of the
joint.
The disorder is a chronic recurring condition that varies in severity
from minor localized patches to complete body coverage. Fingernails and
toenails are frequently affected (psoriatic nail dystrophy) and can be
seen as an isolated symptom. Psoriasis can also cause inflammation of
the joints, which is known as (psoriatic arthritis). Ten to fifteen
percent of people with psoriasis have psoriatic arthritis.
The cause of psoriasis is not fully understood, but it is believed to
have a genetic component and local psoriatic changes can be triggered by
an injury to the skin known as Koebner phenomenon. Various
environmental factors have been suggested as aggravating to psoriasis
including stress, withdrawal of systemic corticosteroid, excessive
alcohol consumption, and smoking but few have shown statistical
significance. There are many treatments available, but because of its
chronic recurrent nature psoriasis is a challenge to treat. You can find more information
Here!
Got It, So What's The Cure?
Wait Let me stop you there! I'm sorry but there is no cure. There are things that can help you
cope with it but for a cure, you will not find one.
You will always be looking for one, and that is part of the problem with psoriasis There are people who know you will be
desperate to find a cure, and they will tell you exactly what you want to hear in order to get your money. If there is a
cure then a genuine person who has ever suffered with psoriasis would give you the information for free. Most so called cures
are nothing more than a diet and lifestyle change or a very expensive moisturiser. Check out the threads in
Natural Treatments first and save your money.
Great so now what? It's not all bad news, come and join others at Psoriasis Club and talk about it. The best help is from accepting it and talking
with others who understand what you're going through. ask questions read through the threads on here and start claiming
your life back. You should also get yourself an appointment with a dermatologist who will help you find something that can
help you cope with it. What works for some may not work for others
It is also not a fast-acting treatment, so if you're looking for a quick fix, this isn't it.
But I do think it's safer than almost any other treatment out there - and Germany has been using this therapy for over 20 years.
My own dermatologist has had 3 patients who were prescribed Fumaderm for a period of 3-4 years, whose psoriasis symptoms did not return once they ended treatment.. at least this is what he told me.. whether it's true or not I cannot say.. but he is a very good doctor and treats me with the utmost care, so I would have a hard time calling him a liar.
Having been treated with Fumaderm now for 3 months, I can see a slow but steady improvement in my condition. When I started on the old forum, my Psoriasis Score was 37.
Today it is 23.
In the next few months, I aiming for 0.
Edit by Fred: This is a split thread from: Fumaderm
Hi all, not been available much lately, been very busy.
Hope everyone is well, apart from the obvious.
Oh, and a thanks to Fred for remembering my birthday in May.
Regards to all......
Posted by: Isabelle - Thu-29-09-2011, 14:31 PM
- No Replies
I am re-starting this thread from the old forum, since this is my current psoriasis treatment.
What is Fumaderm?
Fumaderm® (fumaric acid esters) tablets are licensed in Germany for the treatment of adults with moderate to severe plaque psoriasis for whom topical therapy is ineffective.
It is beneficial in patients with moderate to severe psoriasis, particularly chronic plaque, guttate or pustular disease; at least 50% of patients treated with Fumaderm® will have a reduction of about 70% or more in Psoriasis Area and Severity Index (PASI) score after 16 weeks of treatment.
Data from controlled and observational studies show Fumaderm® is effective as a first-line systemic agent in patients not responding to topical therapy, as an alternative to other systemic agents that are ineffective or not tolerated.
Adverse effects, including diarrhoea, abdominal pain and facial flushing, are common at the start of treatment with Fumaderm® and lead to discontinuation and/or non-compliance in 30 to 40% of patients.
Reversible leucopenia, lymphopenia and transient eosinophilia are frequently observed. Observational studies following patients for up to 14 years do not indicate that Fumaderm® is associated with serious or permanent adverse effects. Increases in serum creatinine and liver function tests occur rarely and resolve with continued treatment or on dose reduction.
EDIT By Fred: Jim has also made a thread from the prescribing leaflet that may be of interest. Fumaderm leaflet
Posted by: Fred - Thu-29-09-2011, 12:45 PM
- Replies (14)
Ever since first getting psoriasis over 30 years ago I have often tried to work out what triggers a Flare Up !
I have tried keeping a diary of foods / drinks / emotional state / health / weather / etc / etc. but I just can not get an exact answer. I have found being wound up about something doesn't help but still can't say for definite that it caused the flare up.
After more research I have found the following things seem to be the most recognised triggers. but even they can sometimes contradict each other.
Trauma: Injury to the skin, including excessive scratching, may trigger a patch of psoriasis to develop. The development of psoriatic plaques at a site of injury is known as What is Koebner reaction ?
Weather: Cold Dry Wind is the worst for psoriasis. and although Sunlight is generally good for psoriasis you should be careful not to over do it as sunburn is a skin injury.
Hormone changes in women: Psoriasis in women tends to be worst during puberty and during the menopause. These are times when there are some major changes in female hormone levels. Some pregnant women with psoriasis find that their symptoms improve when they are pregnant, but it may flare up in the months just after having a baby. Again, this is thought to be related to changes in hormone levels.
This list is not endless and if you have some triggers to add please post them here so we can keep them together.
Oh and by the way I never did find what triggers my flare ups, and I have now given up trying to find out. I don't have so many since giving up tying to work it out! so maybe I should add Don't bother trying to work it out in the "Emotional State" list.
Posted by: Fred - Thu-29-09-2011, 12:29 PM
- Replies (7)
The Koebner phenomenon is perhaps one of the most widely known phenomena in dermatology. It was described for the first time in 1872 by Heinrich Koebner, a well-known 19th century dermatologist, who gave it his name. Some of his patients had developed psoriasis on the site of an excoriation (an abrasion of the skin due to scratching), a bite by a horse or a tattoo.
The term is used to describe the response whereby new lesions appear and develop in patients suffering from skin conditions on healthy skin which has suffered a trauma. A trauma to a "normal" area of skin in a patient with psoriasis can hence lead to new lesions that are identical to those caused by the condition. This is why the Koebner phenomenon is also known as an "isomorphic reaction" (meaning a reaction in the same form).
The Koebner phenomenon is associated with several dermatological conditions, and most frequently with psoriasis, lichen planus and vitiligo. People with psoriasis are hence particularly vulnerable, and those with unstable or erythematic psoriasis, characterised by dark red patches all over the body, are especially at risk.
It should be noted that local traumas do not necessarily trigger this response.
The Koebner phenomenon usually appears between 10 and 14 days after a trauma to the skin, but it can appear up to several years afterwards. Other characteristics are that it does not affect any area in particular, appears most commonly in winter and especially affects children.
Various traumas can trigger this response. It has been observed at the site of bites by dogs and insects, abrasions, gunshot wounds, lacerations, burns, scars, friction, contact dermatitis, in the area rubbed by the elastic of a sock and also after the skin has been shaved, exfoliated or waxed.
The arms of glasses can cause a Koebner response behind the ears. Filing or manicuring the nails can exacerbate psoriasis of the nails. In one case friction by a tennis racket caused a Koebner phenomenon to appear in the right hand palm of a tennis player. Even when someone has psoriatic arthritis, friction by a wedding ring can lead to psoriatic lesions appearing solely on the ring finger.
In the case of palmoplantar psoriasis, lesions due to the Koebner phenomenon may be concentrated on pressure areas, and not be present on the arch of the foot. Sunburn can also lead to psoriasis spreading massively over the body, known as the photo Koebner phenomenon.
Many dermatoses can cause the Koebner phenomenon, including psoriasis, dermatitis, eczema, herpes, lichen planus, chickenpox and vitiligo. Eczema may therefore trigger psoriatic lesions. Finally, an allergic reaction to flu or tuberculosis vaccination, certain drugs, hair spray or hair dye, a tattoo, urticaria and some therapies such as UV therapy can also lead to a Koebner response.
Doctors sometimes talk about a reverse Koebner phenomenon when a psoriatic plaque clears after a trauma as may occur after rubella, a cold, acute pharyngitis or an operation.
Although external occurrences of the Koebner phenomenon are most well known, it can also be invisible and located on a nerve in close proximity with the site of an eruption. For example, a wrist fracture or isolated arthrosis can lead to psoriatic lesions on the nails. This is known as a deep Koebner phenomenon which is a rare phenomenon that should not be ignored.
Posted by: Fred - Wed-28-09-2011, 19:23 PM
- No Replies
Irish actress Jenny Kavanagh has revealed details of her 15 year experience with psoriasis at the launch of an educational campaign aimed at dispelling the myths associated with the skin condition. Jenny, better known for her portrayal of the character Cleo in the hit RTE soap Fair City, launched the initiative – which includes the results of a survey on the public's attitudes towards psoriasis – at the 80th Annual National Ploughing Championships in Athy, Co.Kildare.
The educational campaign, entitled 'Psoriasis - Clear as Mud' and supported by LEO Pharma, seeks to create a better understanding of the skin condition among the general public and those living with psoriasis. Dermatology nurses and the Psoriasis Association of Ireland provided information on the condition and educating the public at a dedicated 'Psoriasis – Clear as Mud' stand at the 2011 National Ploughing Championships.
The need to dispel misconceptions was underlined by the survey's results which revealed the extent to which worrying misunderstandings exist on this common skin condition. The campaign title reflects how this 'muddying of the waters' makes living with psoriasis increasingly difficult. An outspoken psoriasis advocate, Jenny urged Irish people with psoriasis to visit their healthcare professional early for treatment and support. "Having had psoriasis since I was eight years old, I understand the frustration and embarrassment that can sometimes be associated with the condition. That's why I am personally happy to be involved in this worthwhile campaign – I want to show people that psoriasis does not have to be restricting, psoriasis is treatable and there is help available so it is important to seek support early", the 23 year old actress said.
Awareness and attitudes research carried out recently by Behaviour and Attitudes suggests that a number of misconceptions concerning the condition still exist. While most respondents recognised that psoriasis was a debilitating skin condition, 9% believed psoriasis was a liver disease. The survey also revealed that 7% of adults actually believe that psoriasis may actually be contagious while another 7% of adults felt that people suffering from psoriasis should be banned from certain occupations, particularly those working with foods, such as chefs, or personal care In addition, 39% of male and just 18% of female sufferers say that they don't see healthcare professional in relation to their psoriasis which emphasizes the need to educate the public, particularly men with the condition, on the advances in treatments available.
Also speaking at the launch of the campaign was former farmer Ronan Farrelly, a committee member of the Psoriasis Association Ireland and a sitting board member of EUROPSO, the federation of psoriasis patients' associations based in Europe. "This campaign sets out to remove the stigma surrounding psoriasis and educate the public on this condition. The public need to know that psoriasis is a common skin disorder affecting more than 100,000 people in Ireland. It is not contagious and anyone can develop it.
"This initiative will seek to dispel the myths surrounding psoriasis. Those of us with the condition often feel frustrated with the treatment they receive from people who do not understand the condition. This can often lead to a sense of hopelessness. The understanding that will come from this campaign coupled with information about support networks will help people with their treatment and improve overall care of this condition" he added.
Posted by: Fred - Wed-28-09-2011, 18:55 PM
- No Replies
Janssen Biotech, Inc. announced today that STELARA® (ustekinumab) has been awarded the prestigious 2011 Prix Galien USA Award in the category of Best Biotechnology Product. The Prix Galien USA Award recognizes extraordinary efforts in biopharmaceutical and medical technology research and development by honoring biomedical advances impacting both individuals and public health in the past decade.
Approved in the United States by the U.S. Food and Drug Administration (FDA) in September 2009 for the treatment of adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, STELARA is a human monoclonal antibody that selectively targets two cytokines, interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are believed to play a role in the development of psoriasis.
"It is a tremendous honor to have STELARA recognized by the Prix Galien Committee as the Best Biotechnology Product," said Jay P. Siegel, M.D., Chief Biotechnology Officer and Head, Global Regulatory Affairs, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), one of the Janssen pharmaceutical companies. "This achievement is representative of the drive, dedication and commitment of a global team of scientists spanning discovery, research, development and manufacturing."
"The unique mechanism of action of STELARA and the extensive psoriasis clinical program conducted underpin our continued commitment to innovation and developing additional treatment options in immunology," added Susan Dillon, Ph.D., Global Therapeutic Area Head, Immunology, J&JPRD.
The Prix Galien Award recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines and devices, and is considered the industry's highest accolade. Prix Galien was first established in 1970 by French pharmacist Roland Mehl and was inaugurated in the United States in September 2007. The Prix Galien USA award committee comprises eleven individuals including Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals.
"STELARA represents our company's commitment to patients by bringing innovative solutions to market for the treatment of immune-mediated diseases like psoriasis," said Robert Bazemore, President, Janssen Biotech, Inc. "We are honored to be recognized for the significant contribution STELARA has made to the biopharmaceutical community, and importantly to patients in the U.S. who have benefited from this biologic medicine."
Posted by: Fred - Wed-28-09-2011, 14:28 PM
- No Replies
A PROJECT to raise the profile of a painful skin disease has received a boost from an influential former MSP.
Ex-Wester Hailes GP Dr Ian McKee chaired a briefing for politicians on psoriasis, which was attended by scores of patients and nurses.
It is estimated the condition, which can cause difficulties with arthritis, affects more than 20,000 people in the Lothians.
The stigma attached to having a skin condition is also putting pressure on patients, adding to the challenges of the illness.
The charity PSALV wants more attention paid to it and support given to sufferers, and its bid has been backed by Dr McKee.
He said: "Psoriasis is one of the most common of all conditions yet one which most people know very little about. Part of the reason for this general ignorance is the sad fact that many people with this skin condition go to great lengths to keep it a secret because of the cruel reaction they often experience."
Posted by: Fred - Wed-28-09-2011, 12:34 PM
- No Replies
This database was compiled in 2004 and the statistics are derived from official causes of death by psoriasis detailed on certificates of death by each country.
Posted by: Fred - Mon-26-09-2011, 17:33 PM
- No Replies
-Cellceutix Corporation, a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, today released pictures of its mice study with KM-133, the Company’s small molecule acting on the principles of immune stimulation and PRINS reduction as a new treatment for psoriasis. The pictures are available for viewing at " cellceutix.com/product-candidates/km-133---psoriasis-compound.html " The pictures show a dramatic response to treatment with KM-133. In the studies 100% of the mice responded to the treatment.
The Company also reported that it has engaged its FDA consultant for the purpose of preparing a regulatory pathway with the U.S. Food and Drug Administration (“FDA”) pursuant to Section 505(b)(2) for KM-133, as a new treatment for psoriasis.
Given the fact that the active moiety of KM-133 is an already FDA-approved product, Cellceutix believes that it will be eligible for a 505(b)(2) regulatory pathway, which permits compounds in development to be taken into advanced stages of clinical trials based upon bioequivalence from previously reported filings; saving time and money in the development process.
Research of a human xenograft animal model of psoriasis conducted by Cellceutix on KM-133 measuring it against methotrexate, a commonly used drug today in the treatment of psoriasis, showed a faster reduction of lesion appearance (84% versus 63%), a greater reduction in serum PRINS (96 versus 48%) and a significant reduction in serum IL-20 (87% versus 46%) in models treated with KM-133 as compared to methotrexate. More importantly, psoriasis lesions showed no reoccurrence in models treated with KM-133 throughout the 180-day study whereas psoriasis lesions reappeared in those treated with methotrexate in 61 days.
“Now that we have Kevetrin firmly on course for human trials, we can dedicate resources towards other drugs in our pipeline,” commented Cellceutix CEO Leo Ehrlich. “The psoriasis market is a multi-billion dollar opportunity in which we feel we have a competitive edge based upon our pre-clinical data of KM-133 outperforming today’s standards of treatment. The results on the mice were beyond our most optimistic expectations. Most importantly the study used a ‘human xenograft” animal model of psoriasis. We have signed confidential agreements with some large pharmas who have already shown interest in KM-133. Our belief is that based on the chemistry of KM-133, it meets the eligibility for 505(b)(2) clearance which means that we could have two extremely promising drugs in clinical trials in 2012, with KM-133 potentially being in Phase II/III trials. I am excited about all of the developments happening at Cellceutix and look forward to providing shareholders with frequent updates over the coming weeks.”
Posted by: Fred - Mon-26-09-2011, 17:08 PM
- No Replies
Warnex Inc. (TSX: WNX) announced today that its Bioanalytical Services division participated in the international External Quality Assessment Scheme (DEQAS) and has received certification from DEQAS for the analysis of vitamin D (25-hydroxyvitamin D).
"With the increased attention on health issues related to vitamin D, the demand for vitamin D testing has risen dramatically in the past few years," said Mark Busgang, President and CEO of Warnex. "Warnex provides a highly accurate method for the detection of vitamin D. We are pleased to obtain this certification, which demonstrates our continued commitment to providing quality science and results to our customers".
The analysis of 25-hydroxyvitamin D is one of the most accurate ways to determine the level of vitamin D is the body. Warnex uses high performance liquid chromatography (HPLC) combined with mass spectrometry (MS/MS) to measure 25-hydroxyvitamin D2 and D3 in human blood plasma.
By participating in DEQAS, Warnex demonstrated that its HPLC/MS/MS method is reliable with respect to absolute values, assay linearity, as well as assay precision, and can be used with confidence by clinicians to assess vitamin D deficiency in patients.
Vitamin D deficiency, which results from inadequate nutritional intake of vitamin D and inadequate sunlight exposure, leads to bone softening diseases such as rickets in children and osteomalacia and osteoporosis in adults. Vitamin D has also been linked to many other conditions, including certain cancers, type 1 diabetes, multiple sclerosis, tuberculosis, Alzheimer's disease, psoriasis, and all-cause mortality.
Posted by: Fred - Sun-25-09-2011, 21:43 PM
- Replies (1)
Psoriasis Club does not allow links.
The forum is self funded and we want the search engines to stay here and not go to other websites, (especially to websites that hire spammers to plague forums like this). It costs money to run this site and we are not paying to advertise other websites.
We don't want to stop you posting links to websites that could offer good information to others, and we know most of you are genuine. But we do get some members just wanting to post links to get traffic back to their websites, so we have chosen to disallow live links on this website completely.
You can post links that others can copy and paste by using the "SC" or "WB" buttons, see here for more information: Added two new codes for outside links. Obviously Internal links are fine and I will make them live. (If I do happen to miss one please let me know) *Spam links WILL be removed.
We appreciate your help in this and are sure you will understand that this option is better for the forum and it's members in the long term as it will help combat spam, and people will still be able to find the website without us loosing traffic.
Members are welcome to contact me and we can talk about posting a link to their website in the links page, or making a link live.
IMPORTANT: When you sign up for registration you have agreed to the conditions quoted below! so if you're joining just to post links, I suggest you think again as you will be damaging your IP, Email, and Websites reputation.
Quote:Important we do not allow links to affiliation programs, other websites, or miracle cures. if you are joining with the intention of posting such links or any form of Spamming or Trolling you will be banned without question, and your registration details could be listed on stopforumspam.com
Thank you for understanding.
Fred.
P.S You will also notice we don't allow signatures for the same reason.
EDIT: You can now post internal links, please see: Internal linking
Posted by: Fred - Sat-24-09-2011, 13:10 PM
- No Replies
Johnson & Johnson (JNJ) won U.S. approval for an expanded use of Remicade to treat children with a chronic inflammatory bowel disease who don’t respond to traditional therapy.
The Food and Drug Administration cleared the medicine chemically known as infliximab for pediatric ulcerative colitis, the company said today in a statement.
Remicade was approved in 1998 as the first anti-tumor necrosis factor (TNF)-alpha treatment in the U.S. It is used in Crohn’s disease in adults and children, and ulcerative colitis, rheumatoid arthritis and psoriasis in adults. Most children with ulcerative colitis are first treated with anti-inflammatory drugs and with steroids, according to the Pediatric IBD Foundation.
“Ulcerative colitis can be a devastating disease and previously, there had been no approved therapeutic options for pediatric patients who had an inadequate response to conventional therapy,” Jeffrey Hyams, head of digestive diseases and nutrition at Connecticut Children’s Medical Center, said in the statement from New Brunswick, New Jersey-based J&J.
Hyams, also a professor of pediatrics at the University of Connecticut School of Medicine, was the lead investigator in a company-sponsored study that showed 73 percent of children with ulcerative colitis responded to the drug within eight weeks.
About 150,000 children younger than age 17 are living with the symptoms of inflammatory bowel disease, J&J said. Ulcerative colitis can slow growth in children and delay sexual maturation, according to the Mayo Clinic based in Rochester, Minnesota.
Serious Risks
While the drug’s approval provides a new treatment option for children with moderate to severe ulcerative colitis, there are “serious risks” associated with its use because it suppresses the immune system, Donna Griebel, director of the FDA’s Division of Gastroenterology and Inborn Errors Products, said in a statement.
The drug carries a boxed warning, the FDA’s strongest caution, for increased risks of cancer and viral, fungal or bacterial infections.
A rare, often fatal type of cancer called Hepatosplenic T- cell Lymphoma is among malignancies that have been reported in adolescent and young adult patients using TNF blockers, the agency said in the statement.
An FDA advisory panel on July 21 backed Remicade for pediatric ulcerative colitis to induce and maintain clinical remission and induce mucosal healing. The panel didn’t recommend the therapy to maintain mucosal healing or eliminate corticosteroid use. The medicine generated $4.6 billion in revenue last year, according to data compiled by Bloomberg.
Posted by: Fred - Sat-24-09-2011, 13:00 PM
- No Replies
Psoriasis is a stronger predictor of elevated cholesterol in children than is body weight, according to an analysis of electronic medical records from Kaiser Permanente Southern California (KPSC). The findings reinforce the need for physicians to address the condition as a systemic metabolic disorder rather than as a superficial skin disease.
The study examined the records of 710,949 children ages 2 through 19 who had at least one visit to KPSC that recorded height and body weight during the years 2007 and 2008. It identified those with a coding for psoriasis or a prescription associated with the treatment of psoriasis; a chart review confirmed the diagnosis in 1,350 patients.
The patient records were stratified into categories of underweight, normal weight, overweight, moderately obese and extremely obese using standard age-adjusted BMI criteria. Excessive body weight was associated with a higher odds for psoriasis. Analyses found the odds ratios for psoriasis were 0.68, 1.00, 1.31, 1.39 and 1.78, respectively.
The odds ratios for severe psoriasis, as assessed by use of systemic therapy or phototherapy by 53 patients, were 0.00, 1.00, 2.78, 2.93 and 4.19, respectively.
Comparing those characterized as overweight to extreme obese to normals, adolescents (ages 12 to 19) with psoriasis had significantly higher mean total cholesterol (P = .020), LDL cholesterol (P = .007), triglycerides (P = 0.14) and ALT (P = .016) than those who did not have psoriasis. The differences were moderate but significant. There was no significant difference between the two groups with regard to HDL.
"I think the most important point for clinicians is that teens with psoriasis have higher cholesterol levels, regardless of their body weight, and this may be a risk factor for cardiovascular disease," says Corinna Koebnick, Ph.D., research scientist at the KPSC's Department of Research & Evaluation and the lead author of the study.
"The second point is that children who are obese have a much higher prevalence of psoriasis. When physicians treat young people for psoriasis, they should monitor for risk factors of cardiovascular disease, especially if the patient is obese," she says.
Posted by: Fred - Fri-23-09-2011, 11:43 AM
- Replies (3)
Psoriasis is an inflammatory disease that affects women in their reproductive years. Other similar diseases have been associated with adverse pregnancy outcomes. We sought to assess whether pregnant women with psoriasis are at higher risk of developing complications, such as preterm birth (PTB) and low birth weight (LBW).
A retrospective cohort, performed at two large tertiary centers, evaluated the outcomes of 162 pregnancies in 122 women with psoriasis and 501 pregnancies in 290 women without psoriasis.
Univariable and multivariable analyses, adjusting for important demographic factors, comorbidities, or a propensity score, were performed to evaluate the association of psoriasis and a poor outcome composite (POC), including PTB (<37 gestational weeks) and LBW (<2,500 g).
Repeated measures analysis was used to account for the multiple pregnancies per woman. Cesarean delivery, preeclampsia/eclampsia, and spontaneous abortion were also evaluated.
For women with psoriasis, there was a 1.89-fold increase in odds of POC (95% CI 1.06–3.39) in the univariable analysis. This effect remained statistically significant in the multivariable analyses. Psoriasis was not associated with cesarean delivery, preeclampsia/eclampsia, and spontaneous abortion.
This study has shown higher odds of POC in patients with psoriasis. Further larger population-based studies are required to confirm these findings.
Posted by: Fred - Thu-22-09-2011, 21:57 PM
- No Replies
We want Psoriasis Club to be a safe friendly forum without spammers, trolls, or bullies and we encourage all our members to help us by reporting problems on the forum!
If you want to report a post for spam, advertising messages, misleading posts, or abuse. click the "Report" button and a window opens.
Choose your reason for reporting a post from the list and click "Report Post" your report will be sent to the moderators. You may be contacted for more information.
If you want to report a member, a members profile, a private message, or any other reason you may think is not in keeping with good forum behaviour. You can click "Report User" from the bottom right of the members profile which you can find by clicking their name.
Posted by: Fred - Thu-22-09-2011, 14:18 PM
- No Replies
Janssen Inc. announced today that Health Canada has expanded the approved indication for SIMPONI® (golimumab), in combination with methotrexate, to include the inhibition of progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who had not previously been treated with methotrexate. Health Canada also approved an expanded indication in the improvement of physical function in adult patients with moderately to severely active rheumatoid arthritis.1 Rheumatoid arthritis is an inflammatory condition that if left untreated, can lead to permanent damage such as joint deformity and disability.2
"This is an exciting and welcome development for Canadians with moderate to severe rheumatoid arthritis," said Dr. Edward Keystone, Professor, Faculty of Medicine, University of Toronto and one of the principal investigators of the studies on which the approval was based. "Inhibiting the progression of the disease and improving physical function, allowing patients to retain their ability to carry out daily tasks, are key considerations in managing this potentially debilitating autoimmune condition."
The new approval is based on data from the Phase 3 GOlimumab Before Employing methotrexate as the First-line Option in the treatment of Rheumatoid arthritis of Early onset (GO-BEFORE) trial that showed the efficacy of SIMPONI®, in a methotrexate-naïve patient population, in reducing the rate of joint damage as evaluated by X-ray; and on data from the Phase 3 GOlimumab FOR subjects With Active RA Despite Methotrexate (GO-FORWARD) trial that showed sustained improvement, in physical function as measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI).3,4,5
A chronic inflammatory condition and autoimmune disease, rheumatoid arthritis affects approximately 300,000 Canadians, with three times as many women as men having the disease.2 It most often develops in young adulthood (ages 25 to 50) and is characterized by symptoms of joint inflammation, stiffness and pain that over time involves more joints on both sides of the body.2 SIMPONI® was first approved in Canada in 2009 for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. SIMPONI® is a 50 mg once-monthly, subcutaneously-administered anti-tumor necrosis factor (TNF)-alpha treatment.1
You have to register before you can post on our site.
Members Images
Join Psoriasis Club
Psoriasis Club is self funded, we don't rely on sponsorship or donations. We offer a safe
friendly forum and are proactive against spammers, trolls, and cyberbullying. Join us here!
No Advertising.
No Corprate Sponsors.
No Requests for Donations.
No Cyber-Bullying.
No Scams or Cures.
No Recruitment Posts.
No promotions or offers.
No Trolls.
No Spam.
Just a small bunch of friendly people with psoriasis sharing information and support.
Forum Statistics
» Members: 978 » Latest member: benni » Forum threads: 7,349 » Forum posts: 268,982
There are currently 244 online users. »0 Member(s) | 243 Guest(s) "YOYO" The Psoriasis Club Bot Is On-line
Psoriasis Cure!
How many people have Psoriasis?
In 2012 there were approximately 36.5 million prevalent cases of psoriasis, and by 2022, GlobalData epidemiologists forecast that this figure will reach approximately 40.93 million.
The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world.
The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy.
Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.
